The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
Open accessAbstract
The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra™), vardenafil (Levitra™), and tadalafil (Cialis™) have been developed for treatment of erectile dysfunction. Moreover, sildenafil and tadalafil are used for the management of pulmonary arterial hypertension in patients. Since our first report showing the cardioprotective effect of sildenafil in 2002, there has been tremendous growth of preclinical and clinical studies on the use of PDE5 inhibitors for cardiovascular diseases and cancer. Numerous animal studies have demonstrated that PDE5 inhibitors have powerful protective effect against myocardial ischemia/reperfusion (I/R) injury, doxorubicin cardiotoxicity, ischemic and diabetic cardiomyopathy, cardiac hypertrophy, Duchenne muscular dystrophy and the improvement stem cell efficacy for myocardial repair. Mechanistically, PDE5 inhibitors protect the heart against I/R injury through increased expression of nitric oxide synthases, activation of protein kinase G (PKG), PKG-dependent hydrogen sulfide generation, and phosphorylation of glycogen synthase kinase-3β - a master switch immediately proximal to mitochondrial permeability transition pore and the end effector of cardioprotection. In addition, PDE5 inhibitors enhance the sensitivity of certain types of cancer to standard chemotherapeutic drugs, including doxorubicin. Many clinical trials with PDE5 inhibitors have focused on the potential cardiovascular and cancer benefits. Despite mixed results of these clinical trials, there is continuing strong interest by basic scientists and clinical investigators in exploring their new clinical uses. It is our hope that future new mechanistic investigations and carefully designed clinical trials would help in reaping additional benefits of PDE5 inhibitors for cardiovascular disease and cancer in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Survival and Development of Neonatal Rat Cardiomyocytes Transplanted into Adult Myocardium
Müller-Ehmsen, J., Whittaker, P., Kloner, R. A., Dow, J. S., Sakoda, T., Long, T. I., Laird, P. W., & Kedes, L. (2002) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2001.1491 · Cited by 481
Grover-Páez, F., Villegas Rivera, G., & Guillén Ortíz, R. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.02.006 · Cited by 53
Rambhatla, A., Kovanecz, I., Ferrini, M., Gonzalez-Cadavid, N. F., & Rajfer, J. (2008) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901588 · Cited by 51
Cited by
Emerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102
Chronic liver diseases and erectile dysfunction
Zang, G., Sun, X., Sun, Y., Zhao, Y., Dong, Y., Pang, K., Cheng, P., Wang, M., & Zheng, Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1092353 · Cited by 21
“PDE5-I can protect the liver from ischemia-reperfusion injury through a variety of signaling pathways, such as increasing intracellular cGMP levels, activating protein kinase C and protein kinase G (93), leading to the activation of cGMP-dependent protein kinase, which in turn induces vasodilation, anti-inflammatory a…”
BackgroundZemel, M. B., Kolterman, O., Rinella, M., Vuppalanchi, R., Flores, O., Barritt, A. S., Siddiqui, M., & Chalasani, N. (2019) · Obesity · doi:10.1002/oby.22346 · Cited by 19
Rebello, C. J., Zemel, M. B., Kolterman, O., Fleming, G. A., & Greenway, F. L. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001303 · Cited by 8
Metadata
- Authors
- Das, A., Durrant, D., Salloum, F. N., Xi, L., & Kukreja, R. C.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 147
- Pages
- 12-21
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2070737114
- Cited by
- 212
- References
- 4
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. https://app.cochat.ai/papers/10.1016/j.pharmthera.2014.10.003
- The paper
- Das, A., Durrant, D., Salloum, F. N., Xi, L., & Kukreja, R. C. (2015). PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2014.10.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.